Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia

Leukemia Research

Volumn 47, Issue , 2016, Pages 78-83

  Chavez, Julio C ^a   Piris Villaespesa, Miguel ^a   Dalia, Samir ^a   Powers, John ^a   Turba, Elyce ^a   Nodzon, Lisa ^a   Komrokji, Rami ^a   Sokol, Lubomir ^a   Locke, Frederick L ^a   Lancet, Jeffrey ^a   Sotomayor, Eduardo M ^a   Kharfan Dabaja, Mohamed A ^a   Pinilla Ibarz, Javier ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CLL; Lenalidomide; Refractory; Rituximab

Indexed keywords

LENALIDOMIDE; RITUXIMAB; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION; INFUSION RELATED REACTION; INSOMNIA; LEUKEMIA RELAPSE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHY; NEUTROPENIA; NIGHT SWEAT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SEPSIS; SINUSITIS; THROMBOCYTOPENIA; TUMOR FLARE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; PROCEDURES; REMISSION; SALVAGE THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; REMISSION INDUCTION; RITUXIMAB; SALVAGE THERAPY; THALIDOMIDE;

EID: 84973278445     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2016.05.012     Document Type: Article

References (21)

1. Badoux X.C., Keating M.J., Wang X., O'Brien S.M., Ferrajoli A., Faderl S., Burger J., Koller C., Lerner S., Kantarjian H., Wierda W.G. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011, 117:3016-3024.
2. Badoux X.C., Keating M.J., Wen S., Wierda W.G., O'Brien S.M., Faderl S., Sargent R., Burger J.A., Ferrajoli A. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2013, 31:584-591.
3. Bergmann M.A., Goebeler M.E., Herold M., Emmerich B., Wilhelm M., Ruelfs C., Boening L., Hallek M.J. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005, 90:1357-1364.
4. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., Grant B., Sharman J.P., Coleman M., Wierda W.G., Jones J.A., Zhao W., Heerema N.A., Johnson A.J., Sukbuntherng J., Chang B.Y., Clow F., Hedrick E., Buggy J.J., James D.F., O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2013, 369:32-42.
5. Chanan-Khan A., Miller K.C., Musial L., Lawrence D., Padmanabhan S., Takeshita K., Porter C.W., Goodrich D.W., Bernstein Z.P., Wallace P., Spaner D., Mohr A., Byrne C., Hernandez-Ilizaliturri F., Chrystal C., Starostik P., Czuczman M.S. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J. Clin. Oncol. 2006, 24:5343-5349.
6. Chen C.I., Bergsagel P.L., Paul H., Xu W., Lau A., Dave N., Kukreti V., Wei E., Leung-Hagesteijn C., Li Z.H., Brandwein J., Pantoja M., Johnston J., Gibson S., Hernandez T., Spaner D., Trudel S. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J. Clin. Oncol. 2011, 29:1175-1181.
7. Ferrajoli A., Lee B.N., Schlette E.J., O'Brien S.M., Gao H., Wen S., Wierda W.G., Estrov Z., Faderl S., Cohen E.N., Li C., Reuben J.M., Keating M.J. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
8. Fischer K., Cramer P., Busch R., Stilgenbauer S., Bahlo J., Schweighofer C.D., Bottcher S., Staib P., Kiehl M., Eckart M.J., Kranz G., Goede V., Elter T., Buhler A., Winkler D., Kneba M., Dohner H., Eichhorst B.F., Hallek M., Wendtner C.M. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 2011, 29:3559-3566.
9. Furman R.R., Sharman J.P., Coutre S.E., Cheson B.D., Pagel J.M., Hillmen P., Barrientos J.C., Zelenetz A.D., Kipps T.J., Flinn I., Ghia P., Eradat H., Ervin T., Lamanna N., Coiffier B., Pettitt A.R., Ma S., Stilgenbauer S., Cramer P., Aiello M., Johnson D.M., Miller L.L., Li D., Jahn T.M., Dansey R.D., Hallek M., O'Brien S.M. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2014, 370:997-1007.
10. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., Kipps T.J. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
11. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., Hensel M., Hopfinger G., Hess G., von Grunhagen U., Bergmann M., Catalano J., Zinzani P.L., Caligaris-Cappio F., Seymour J.F., Berrebi A., Jager U., Cazin B., Trneny M., Westermann A., Wendtner C.M., Eichhorst B.F., Staib P., Buhler A., Winkler D., Zenz T., Bottcher S., Ritgen M., Mendila M., Kneba M., Dohner H., Stilgenbauer S. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
12. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010. CA. Cancer J. Clin. 2010, 60:277-300.
13. Keating M.J., O'Brien S., Kontoyiannis D., Plunkett W., Koller C., Beran M., Lerner S., Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma 2002, 43:1755-1762.
14. Lin K.I., Tam C.S., Keating M.J., Wierda W.G., O'Brien S., Lerner S., Coombes K.R., Schlette E., Ferrajoli A., Barron L.L., Kipps T.J., Rassenti L., Faderl S., Kantarjian H., Abruzzo L.V. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009, 113:3168-3171.
15. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., Rimsza L., Heaton R., Knight R., Zeldis J.B. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 2005, 352:549-557.
16. Morton L.M., Wang S.S., Devesa S.S., Hartge P., Weisenburger D.D., Linet M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
17. Robak T., Dmoszynska A., Solal-Celigny P., Warzocha K., Loscertales J., Catalano J., Afanasiev B.V., Larratt L., Geisler C.H., Montillo M., Zyuzgin I., Ganly P.S., Dartigeas C., Rosta A., Maurer J., Mendila M., Saville M.W., Valente N., Wenger M.K., Moiseev S.I. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 2010, 28:1756-1765.
18. Rozman C., Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med. 1995, 333:1052-1057.
19. Sher T., Miller K.C., Lawrence D., Whitworth A., Hernandez-Ilizaliturri F., Czuczman M.S., Miller A., Lawrence W., Bilgrami S.A., Sood R., Wood M.T., Block A.W., Lee K., Chanan-Khan A.A. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk. Lymphoma 2010, 51:85-88.
20. Sorror M.L., Storer B.E., Maloney D.G., Sandmaier B.M., Martin P.J., Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008, 111:446-452.
21. Zonder J.A., Crowley J., Hussein M.A., Bolejack V., Moore D.F., Whittenberger B.F., Abidi M.H., Durie B.G., Barlogie B. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010, 116:5838-5841.